Another thematic ETF launches to target global obesity battle

Another thematic ETF launches to target global obesity battle
The fund will invest in stocks of drug manufacturers and related industries.
MAY 21, 2024

The growing global concern about obesity and its impact on other health related matters is driving a surge in companies developing solutions.

For investors seeking thematic funds focused on the sector there are several options, but there is room for more and Amplify ETFs is the latest to launch an index-based fund offering exposure to those in what is known as GLP-1 treatments.

The firm, which has over $9 billion assets under management and acquired a suite of specialty funds last summer from ETF Managers Group, has announced the launch of the Amplify Weight Loss

Drug & Treatment ETF (NYSE: THNR).

The fund tracks the VettaFi Weight Loss Drug & Treatment Index which allocates 70% of drug manufacturers, those who are launching or testing GLP-1 treatments. The other 30% is allocated to ‘enablers’ or companies engaged in outsourced development and manufacturing, measurement and analysis, and/or distribution or administration of GLP-1 drugs.

With an estimated one billion people globally defined as obese and the World Health Organization recently reporting that the figure had doubled in the period 1990-2022, the scope for returns from those companies offering solutions is clear.

Last month, another niche ETF provider also launched a thematic fund focused on GLP-1 treatments. The renamed Tema Obesity and Cardiometabolic ETF trades on the Nasdaq with the ticker HRTS.

However, the thematic funds market has seen some pullback recently following the surge of interest in specialities such as work from home funds which gained during the pandemic. Investors have already yanked nearly $4 billion so far this year from exchange-traded funds investing in themes like clean energy and cloud computing, after withdrawing $4.6 billion from such funds as a whole in 2023, according to Bloomberg Intelligence. There is expectation that a rebound will come once investors recover from over-allocation to some themes which turned out to be ‘micro-bubbles’.

Latest News

Fintech bytes: AI tools for advisors flag when clients need attention
Fintech bytes: AI tools for advisors flag when clients need attention

DeepVest, Asset-Map and Aidentified launch automation that spots household gaps, wealth events and portfolio triggers for advisor sign-off

AI 'leadership swirl' distracts wealth execs from growth, says Bridge CEO
AI 'leadership swirl' distracts wealth execs from growth, says Bridge CEO

Eddie Brown says RIA executives need AI built for strategy and execution, not just advisor productivity

RIA moves: Summit, UWP deals keep founders in charge; SagePoint adds RISE
RIA moves: Summit, UWP deals keep founders in charge; SagePoint adds RISE

Independent advisors in Colorado, Texas and Arkansas join larger wealth management platforms through acquisitions and partnerships

SEC censures Pacific West sales agent but declines industry bar
SEC censures Pacific West sales agent but declines industry bar

The enforcement division wanted a full bar - the Commission went lighter

CW Advisors buys $920M Woburn RIA, its seventh deal under Osaic
CW Advisors buys $920M Woburn RIA, its seventh deal under Osaic

Welch brothers’ 93 Financial Group gives the Osaic-owned RIA a fifth greater Boston office, days after a $1.6B triple acquisition

SPONSORED The new retirement challenge: Preparing for a longer future

Advisors are broadening the conversation beyond savings to help clients prepare for the realities of longer lives

SPONSORED Best Practices for Engaging Women Around Alternatives

Growing wealth, evolving priorities, and untapped opportunities are reshaping how women approach long-term investing.